CCO--Direct-Acting Antivirals in Treatment-Naive HCV Patients

New @ CCO
**Free registration required

Direct-Acting Antivirals in Treatment-Naive HCV Patients
Mark S. Sulkowski, MD, reviews the latest data on and the approved indications of telaprevir and boceprevir in treatment-naive, genotype 1 HCV–infected patients.

Learning Objectives
Upon completion of this activity, participants should be able to:
Outline the new standard of care of HCV protease inhibitor-based therapy for treatment-naïve genotype 1 HCV-infected patients
Apply findings from phase III clinical trials of boceprevir and telaprevir in treatment-naive patients with genotype 1 infection
Integrate the concept of response-guided therapy with boceprevir and telaprevir into clinical practice
Appraise strategies to manage adverse effects in patients receiving peginterferon/ribavirin plus either boceprevir or telaprevir
Provide accurate and appropriate counsel as part of the treatment team
Provide appropriate care and counsel for patients and their families

Clinical Options

http://www.clinicaloptions.com/Hepatitis/Annual%20Updates/2011%20Annual%20Update.aspx